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Introduction
The adrenal gland is well known to be a target for
angiotensin II (Ang II). Ang II  is the main regulator of
aldosterone secretion  and exerts the stimulatory effect
on the adrenal  cell growth [1-3]. Although the adrenal
gland is affected by circulating Ang II, the peptide can
be also generated  within the gland by a local renin-
angiotensin system [4,5].  Both main subtypes of Ang II
receptors, AT1 and AT2 were identified in rodent and
human adrenal cortex and medulla [6-8]. In adrenal cor-
tex, AT1 subtype is prevalent, whereas in adrenal
medulla the AT2 subtype dominates [6]. Despite the
important roles of Ang II and its receptors in the adrenal
physiology, the data on  angiotensin receptors in the
adrenal tumors are rather scarce and partly controversial
[9-14].These investigations were performed by means
of radioligand binding or by means of molecular biolo-
gy techniques, mainly polymerase chain reaction
(PCR). On the other hand, the study performed by
means of immunohistochemistry is lacking. The present
paper reports, for the first time, the expression of
angiotensin receptors AT1 and AT2 in human adrenal
tumors as revealed by immunohistochemistry.
Materials and methods
Tumor material. The archival material of  26 surgically excised
adrenal tumors in years 2001-2006, stored in paraffin blocks was
studied. The material included 3 hyperplasias,  8 non-functioning
cortical adenomas, 3 cortical adenomas manifesting themselves as
primary hyperaldosteronism (Conn's syndrome), 4 cortisol-secret-
ing adrenocorical adenomas, causing the Cushing's syndrome, 
3 hormonally non-functioning adrenal cancers and 5 pheochromo-
cytomas.  In addition, 6 non-tumoral adrenal glands were studied.
Five of them were  removed from patients  suffering from renal
cancers during the surgical excision of the affected kidney, and one
was excised together with  pheochromocytoma.
Immunohistochemistry. The paraffin sections were immunos-
tained with antibodies raised against AT1  and AT2 receptor pro-
teins. AT1 immunostaining was performed using the  anti-AT1
polyclonal antibody (sc-1173), raised against the N-terminal
extracellular  domain of AT1 receptor and recognizes  human, rat
and mouse receptor protein. AT2 receptors were revealed using
the sc-9040 polyclonal antibody  raised against the 221-303 frag-
ment of the human AT2 receptor protein. The antibody detects
human, rat and mouse AT2 receptors. Both antibodies were pur-
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chased from Santa Cruz Biotechnology, CA, USA. The anti-AT1
and anti-AT2 antibodies were applied in  working dilution 1:100.
The visualization of  primary antibodies  was done using  the
StreptABComplex/HRP Duet (Dako Cytomation) following the
procedure recommended by the producer. In brief,  the biotiny-
lated goat antibody against rabbit and mouse immunoglobulin
was applied as the secondary antibody, followed by streptavidin-
biotinylated horseradish peroxidase complex and 3,3'-
diaminobenzidine as chromogen. The slides stained without the
primary antibody served as controls.
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Fig. 1. Non-tumoral adrenal gland immunostained with AT1 anti-
body. Positive immunostaining of some cell nuclei and within the
cytoplasm of zona reticularis cells (original magnification 200×).
Fig. 2. Non-tumoral adrenal gland. Immunostaining  with AT2
antibody. Positive staining of cytoplasm of zona reticularis cells
(original magnification 200×). Fig. 3. Cortical adenoma in patient
with Conn's syndrome immunostained with AT1 antibody. Positive
immunostaining mainly in cell membranes and some cell nuclei
(original magnification 400×). Fig. 4. Cortical adenoma in patient
with Cushing's syndrome immunostained with AT2 antibody.
Negative staining of tumoral cells and a strong reaction of intersti-
tial tissues (original magnification 400×). Fig. 5. Adrenal cancer.
Immunostaining with AT1 antibody. Positive immunoreaction lim-
ited to cytoplasm of tumoral cells (original magnification 400×).
Results
The non-tumoral adrenal gland
The investigated fragments were limited to the adrenal
cortex. The positive immunostaining with anti-AT1
antibody was found mainly in cell membranes. In the
cytoplasm, a moderate staining was  detectable in zona
reticularis cells. In  3 from 6 examined glands, the sub-
population of the glandular cell nuclei (1%-31%) also
immunostained with anti-AT1 antibody (Fig. 1). With
anti-AT2 antibody, in all specimens the cell mem-
branes  and cell  nuclei were negative. A weak or mod-
erate reaction was observed  within the cytoplasm of
zona reticularis cells in 3 from 6 glands (Fig. 2). A
weak reaction was also observable in capsule and
interstitial connective tissue, and, in one case, also in
the intra-glandular blood vessels.
Adrenocortical hyperplasia
In all  the samples diagnosed as adrenocortical hyper-
plasia the reaction with anti-AT1 antibody was moder-
ate to strong in cell membranes and weak to strong in
cytoplasm. In all the cases  a percentage of AT-1 posi-
tive cell nuclei was >15% (15%, 30% and 50%,
respectively). On the other hand, there were no reac-
tions with AT-2 antibody either in cell nuclei or in
cytoplasm. The cell membranes were also immuno-
negative. In one case a weak reaction was also noticed
in the interatial tissue and blood vessels.
Non-functioning cortical adenomas
The localization of AT1 receptors was roughly similar
to that in normal adrenal cortex and adrenocortical
hyperplasia. The cell membrane-located immunostain-
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Fig. 6. Adrenal cancer immunostained with AT2 antibody. Negative staining of tumoral cells and strong positive reaction of blood ves-
sels walls (original magnification 400×). Fig. 7. Adrenal cancer stained without primary antibodies (negative control - original magnifi-
cation 400×). Fig. 8. Pheochromocytoma immunostained with AT1 antibody. Weak immunostaining of cytoplasm of the tumoral cells
(original magnification 400×). Fig. 9. Pheochromocytoma immunostained with AT2 antibody. Negative staining of tumoral cells and
strong immunostaining of interstitial tissue (original magnification 400×).
ing was weak or strong, cytoplasmic immunostaining
was weak except one case where the reaction was
strong. The AT1-positive subpopulation of glandular
cell nuclei  was present in all but one tumor; its per-
centage varied from 2% to 50% of  the nuclei. In all
but one adenoma the reaction with anti-AT2 antibody
was negative in cell membranes, cytoplasm and cell
nuclei. In the remaining one case a strong AT2
immunopositivity in cell membranes was observed. In
4 from 8 adenomas , the variable AT2 immunopositiv-
ity was also found in blood vessels and the interstitial
compartment.
Aldosterone- and cortisol-secreting adenomas
The adenomas removed from patients with Conn's
syndrome presented moderate (in one case) or strong
(2 cases) immunostaining of cell membranes with anti-
AT1 antibody (Fig. 3). The subpopulation of AT1-pos-
itive cell nuclei included 4%, 5% and 50%, respective-
ly. The variable immunostaining was noticed within
the glandular cell cytoplasm (weak, moderate or
strong). In contrast, the glandular cells were negative
with anti-AT2 antibody.
In the tumors from patients with Cushing's syn-
drome the variable cell membrane immunostaining
was found: strong in 2 cases, weak in another 2 cases
and negative in one case. A subpopulation of cell
nuclei  was AT1-positive in 3 cases (5%, 6% and 15%
of nuclei, respectively). In the remaining two cases ,
sporadic (<1%) cell nuclei were also immunostained
with AT1 antibody. With AT2 antibody, both aldos-
terone- and cortisol-secreting adenomas were
immunonegative except for  blood vessel and intersti-
tial tissues in some cases (Fig. 4).
Adrenal cancers
In  adrenals cancers, neither cell membranes nor cell
nuclei  were immunostained with anti-AT1 antibody.
However, the  weak to moderate AT1 immunostaining
was present within cytoplasm of the tumoral cells (Fig.
5). With anti-AT2 antibody the tumoral cells were
immunonegative, but in one case   moderate to strong
AT2 immunostaining was observed in the walls of
intratumoral blood vessels  and in the interstitial tissue
(Fig. 6).
Pheochromocytomas
In  pheochromocytomas, neither cell membranes nor
cell nuclei  were immunostained with anti-AT1 anti-
body. The  weak to moderate AT1 immunostaining was
present within cytoplasm of the tumoral cells (Fig. 7).
With anti-AT2 antibody the tumoral cells in majority
of cases were immunonegative. In one case  the small
population of cell nuclei (approx. 3%) was AT2- posi-
tive. In one case, a weak AT2 immunopositivity was
also noticed within the cytoplasm. In majority of cases,
a variable immunopositivity was also observed in the
interstitial tissue and/or blood vessels walls (Fig. 8).
Discussion
The data presented above confirm the earlier findings
that AT1 receptors are present and prevalent over AT2
receptors in the normal human adrenal cortex. AT1
receptors are also expressed in benign adrenal tumors
both non-functioning  and hormone-secreting. This
observation is compatible with  some data  from  ear-
lier papers. Tanabe et al. [8] and Kitamura et al. [12]
reported on the expression of AT1  mRNAs in both
aldosterone- and cortisol-secreting adenomas.
Opocher et al. [11] studied the binding of labeled Ang
II in presence or absence of specific receptor blockers
concluded that Ang II  receptors are  present in both
aldosterone-sereting and cortisol-secreting adenomas,
but in the latter the receptor density is lower than in the
normal adrenal tissue. In turn, Schubert et al. [14]
showed the elevated expression of AT1 mRNA in func-
tioning adrenal adenomas, higher than in the normal
adrenal cortex, but a very low signal in non-function-
ing  tumors. The latter observation stays in opposition
to our finding that the functioning and non-functioning
adrenal adenomas do not differ markedly in the AT1
immunostaining. In adrenal cancers, our main finding
was the altered localization of AT1 immunoreactivity:
disappearance of the membrane-linked  and  nuclear
AT1 staining and slightly increased AT1 immunostain-
ing within the cytoplasm. Such alterations, obviously,
cannot be detected by means of PCR technique, which
reflects only the global content of receptor mRNA.
Moreover, the earlier findings concerning the adrenal
cancers, obtained with PCR technique,  were discor-
dant: very low or undetectable signal in one study [11]
and no significant changes according to the other [14].
The nuclear AT1 immunostaining,  observed some-
times in the normal adrenal cortex and in benign, but
not in  malignant adrenal lesions, is surprising. How-
ever, it is  concordant with earlier observations indi-
cating the presence of a nuclear binding site for Ang II
and its AT1-like properties [15]. Although the role of
this site is still unclear, its involvement in growth-pro-
moting Ang II effects  has been suggested [16].
In pheochromocytomas   AT1 immunostaining  was
detectable in tumoral cells but confined  only to cyto-
plasm. In the earlier studies  AT1 mRNA expression in
pheochromocytoma was very low or undetectable
[11]. In contrast to AT1 receptor protein, the AT2
immunostaining of tumoral cells is undetectable in
almost all adrenocortical tumors and pheochromocy-
tomas. The loss of AT2 immunoreactivity in pheochro-
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mocytomas may be of particular interest, since this
subtype of angiotensin receptor is prevalent in the nor-
mal adrenal medulla.
Moreover, AT2 receptors were  suggested to medi-
ate the Ang II - induced inhibition of cell growth  [17].
The strong reaction with AT2 antibody was found in
some cases in the blood vessel walls and in the inter-
stitial tissue. The reaction was absent in the control
slides stained without primary antibody. However, the
specificity of immunostaining in the interstitial tissue
needs further investigations. If the discussed
immunopositivity is specific, the earlier reports show-
ing the expression of AT2 receptor mRNA in
pheochromocytomas may be, at least in part, false pos-
itive. In turn, the strong expression of  AT2 receptors
in the walls of intratumoral vessels, as observed in
some cases, was also reported by one of us in pituitary
adenomas [18]. Interestingly, the AT2 block has been
recently shown to inhibit  retinal angiogenesis via sup-
pression of the crucial factor involved in this process -
vascular endothelial growth factor (VEGF) [19].  It
suggests that the vascular  over-expression of AT2 may
have a role in tumoral neo-angiogenesis in both pitu-
itary and adrenal tumors. 
To conclude, AT1 and AT2 receptors are expressed
in benign adrenocortical tumors roughly similarly to
the non-tumoral adrenal cortex. It means that Ang II
may affect their function and growth and  be involved
in adrenal tumorigenesis. In contrast, in malignant
adrenocortical tumors  and in pheochromocytomas
(which are often potentially malignant neoplasms) the
expression of Ang II receptors is altered. This alter-
ation may reflect the process of dedifferentiation
linked with malignancy but may also have some patho-
physiological consequences.  
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